<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878277</url>
  </required_header>
  <id_info>
    <org_study_id>18-1874</org_study_id>
    <nct_id>NCT03878277</nct_id>
  </id_info>
  <brief_title>Evaluation of Coffee Therapy for Improvement of Renal Oxygenation</brief_title>
  <acronym>COFFEE</acronym>
  <official_title>Coffee, Renal Oxygenation, Blood Flow and Glomerular Filtration Rate in Early Diabetic Kidney Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 1.25 million Americans have Type 1 Diabetes (T1D), increasing risk for early death from&#xD;
      cardiovascular disease (CVD). Despite advances in glycemic and blood pressure control, a&#xD;
      child diagnosed with T1D is expected to live up to 17 years less than non-diabetic peers. The&#xD;
      strongest risk factor for CVD and mortality in T1D is diabetic kidney disease (DKD). Current&#xD;
      treatments, such as control of hyperglycemia and hypertension, are beneficial, but only&#xD;
      partially protect against DKD. This limited progress may relate to a narrow focus on clinical&#xD;
      manifestations of disease, rather than on the initial metabolic derangements underlying the&#xD;
      initiation of DKD. Renal hypoxia, stemming from a potential metabolic mismatch between&#xD;
      increased renal energy expenditure and impaired substrate utilization, is increasingly&#xD;
      proposed as a unifying early pathway in the development of DKD. T1D is impacted by several&#xD;
      mechanisms which increase renal ATP consumption and decrease ATP generation.&#xD;
&#xD;
      Caffeine, a methylxanthine, is known to alter kidney function by several mechanisms including&#xD;
      natriuresis, hemodynamics and renin-angiotensin-aldosterone system. In contrast, to other&#xD;
      natriuretic agents, caffeine is thought to fully inhibit the local tubuloglomerular feedback&#xD;
      (TGF) response to increased distal sodium delivery. This observation has broad-ranging&#xD;
      implications as caffeine can reduce renal oxygen (O2) consumption without impairing effective&#xD;
      renal plasma flow (ERPF) and glomerular filtration rate (GFR).&#xD;
&#xD;
      There are also data suggesting that chemicals in coffee besides caffeine may provide&#xD;
      important cardio-renal protection. Yet, there are no data examining the impact of&#xD;
      coffee-induced natriuresis on intrarenal hemodynamic function and renal energetics in&#xD;
      youth-onset T1D. Our overarching hypothesis in the proposed pilot and feasibility trial is&#xD;
      that coffee drinking improves renal oxygenation by reducing renal O2 consumption without&#xD;
      impairing GFR and ERPF. To address these hypotheses, we will measure GFR, ERPF, renal&#xD;
      perfusion and oxygenation in response to 7 days of cold brew coffee (one Starbucks® Cold brew&#xD;
      325ml bottle daily [205mg caffeine]) in an open-label pilot and feasibility trial in 10&#xD;
      adolescents with T1D already enrolled in the CASPER Study (PI: Bjornstad).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Oxygenation</measure>
    <time_frame>1 hour</time_frame>
    <description>Measured by BOLD MRI, before and after Lasix injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Perfusion</measure>
    <time_frame>1 hour</time_frame>
    <description>Measured by pCASL MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by Iohexol clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Renal Plasma Flow</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by PAH clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tubular Injury Markers</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by markers of kidney injury in plasma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type1diabetes</condition>
  <condition>Type1 Diabetes Mellitus</condition>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Juvenile Diabetes</condition>
  <condition>Diabetic Nephropathies</condition>
  <condition>Diabetes Complications</condition>
  <condition>Diabetes, Autoimmune</condition>
  <arm_group>
    <arm_group_label>Cold Brew Coffee</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Starbucks® Cold brew - 325ml bottle</intervention_name>
    <description>Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit</description>
    <arm_group_label>Cold Brew Coffee</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Youth with T1D (antibody +) with &lt;10 year duration&#xD;
&#xD;
          -  Age 12-21 years&#xD;
&#xD;
          -  Weight &gt;57 lbs and &lt;350 lbs&#xD;
&#xD;
          -  BMI &gt;5th %ile&#xD;
&#xD;
          -  HbA1c &lt;12%&#xD;
&#xD;
          -  Previous exposure to caffeine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Allergy to shellfish or iodine&#xD;
&#xD;
          -  Severe illness, recent DKA&#xD;
&#xD;
          -  Tachyarrhythmias, ADHD, tremors, tics, Tourette's, arrythmias, insomnia, overactive&#xD;
             bladder&#xD;
&#xD;
          -  eGFR &lt;60 ml/min/1.73 m2 or creatinine &gt; 1.5 mg/dl or history of ACR &gt;300 mg/g&#xD;
&#xD;
          -  MRI Scanning contraindications (claustrophobia, implantable metal devices that are&#xD;
             non-MRI compatible, &gt;350 lbs)&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, sodium-glucose&#xD;
             co-transport (SGLT) 2 or 1 blockers, daily NSAIDs or aspirin, sulfonamides,&#xD;
             thiazolsulfone or probenecid, atypical antipsychotics, steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <results_first_submitted>August 5, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2021</results_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado Denver School of Medicine Barbara Davis Center</investigator_affiliation>
    <investigator_full_name>Petter Bjornstad</investigator_full_name>
    <investigator_title>Assistant Professor - Department of Pediatrics &amp; Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03878277/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cold Brew Coffee</title>
          <description>6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.&#xD;
Starbucks® Cold brew - 325ml bottle: Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cold Brew Coffee</title>
          <description>6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.&#xD;
Starbucks® Cold brew - 325ml bottle: Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Renal Oxygenation</title>
        <description>Measured by BOLD MRI, before and after Lasix injection</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cold Brew Coffee</title>
            <description>6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.&#xD;
Starbucks® Cold brew - 325ml bottle: Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Oxygenation</title>
          <description>Measured by BOLD MRI, before and after Lasix injection</description>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before cold brew</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After cold brew</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Perfusion</title>
        <description>Measured by pCASL MRI</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cold Brew Coffee</title>
            <description>6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.&#xD;
Starbucks® Cold brew - 325ml bottle: Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Perfusion</title>
          <description>Measured by pCASL MRI</description>
          <units>ml/s/100g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before cold brew (Right kidney ASL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After cold brew (Right kidney ASL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before cold brew (Left kidney ASL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After cold brew (Left kidney ASL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate</title>
        <description>Measured by Iohexol clearance</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cold Brew Coffee</title>
            <description>6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.&#xD;
Starbucks® Cold brew - 325ml bottle: Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate</title>
          <description>Measured by Iohexol clearance</description>
          <units>ml/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before cold brew</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After cold brew</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effective Renal Plasma Flow</title>
        <description>Measured by PAH clearance</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cold Brew Coffee</title>
            <description>6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.&#xD;
Starbucks® Cold brew - 325ml bottle: Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Renal Plasma Flow</title>
          <description>Measured by PAH clearance</description>
          <units>ml/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before cold brew</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.08" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After cold brew</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.02" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tubular Injury Markers</title>
        <description>Measured by markers of kidney injury in plasma</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cold Brew Coffee</title>
            <description>6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.&#xD;
Starbucks® Cold brew - 325ml bottle: Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit</description>
          </group>
        </group_list>
        <measure>
          <title>Tubular Injury Markers</title>
          <description>Measured by markers of kidney injury in plasma</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before cold brew (cystatin C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After cold brew (cystatin C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the duration of trial with cold brew (7 days) as well as 24 hours after the last study visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cold Brew Coffee</title>
          <description>6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.&#xD;
Starbucks® Cold brew - 325ml bottle: Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal syncope</sub_title>
                <description>Participant reported experiencing dizziness and lightheadedness during manipulation of peripheral IV by nursing staff during the hyperglycemic clamp. Participant given option to leave or continue in study. Participant chose to finish the study visit.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Petter Bjornstad, M.D., Assistant Professor of Pediatrics and Medicine</name_or_title>
      <organization>University of Colorado School of Medicine</organization>
      <phone>7207774659</phone>
      <email>petter.bjornstad@childrenscolorado.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

